1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals

Lancet

Volumn 352, Issue 9124, 1998, Pages 314-316

  Gazzard, Brian ^a   Moyle, Graeme ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; ZIDOVUDINE;

DRUG EFFICACY; HEALTH CARE QUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; SHORT SURVEY; UNITED KINGDOM; VIRUS LOAD;

EID: 0032566194     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)04084-7     Document Type: Note

References (26)

1. 1 BHIVA Guidelines Co-ordinating committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349: 1086-92.
2. 2 Hammer SM, Hughes MD, Squires K, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency viral load infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-33.
3. 3 Stellbrink H-J on behalf of the Invirase International Phase III Trial (SV-14604) Group. Clinical and survival benefit of saquinavir (SQV) in combination with zalcitabine (ddC) and zidovudine (ZDV) in untreated/minimally treated HIV-infected patients. Sixth European Conference on clincal aspects and treatment of HIV infection, Hamburg, Oct 11-15, 1997 (abstr).
4. 4 National AIDS Manual, 16a Clapham Common Southside, London SW4 7AB, UK. Tel: 0171 627 3200. www.nam.org
5. 5 AIDS Treatment Project, 115-29 Southwark Bridge Road, London SE1 0AX. Tel: 0171 403 4262. www.atp.org.uk.
6. 6 Gazzard B, Moyle G. To sequence or not to sequence? Expert Opin Investig Drugs 1997; 6: 99-102.
7. 7 Moyle GJ, Gazzard BG, Cooper DA, Gatell J. Antiretroviral therapy for HIV infection; a knowledge-based approach to drug selection and use. Drugs 1998; 55: 383-404.
8. 8 Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. JAMA 1998; 280: 78-86.
9. 9 NIH draft guidelines available on www.HIVATIS.org.
10. 10 Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 12: 573-79.
11. 11 Dever LL, Oruwari PA, O'Donavan, Eng RHK. Hyperglycaemia associated with protease inhibitors in HIV-infected patients. 37th Interscience Conference on antimicrobial agents and chemotherapy. Toronto: Canada, Sept 28-Oct 1, 1997: LB-8 (abstr).
12. 12 Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998; 351: 867-70.
13. 13 Miller KD, Janes E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulates associated with use of indinavir. Lancet 1998; 351: 871-75.
14. 14 Singh N, Squier C, Sivek C, Wagner M, et al. Determinants of adherence with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing adherence. AIDS Care 1996; 8: 261-69.
15. 15 Opravil M, DeMasi R, Hill A. Prediction of long-term HIV RNA suppression during zidovudine/lamivudine treatment. International workshop on HIV drug resistance, treatment strategies and eradication. St Petersburg: Florida, USA, 1997: 60 (abstr).
16. 16 Kempf D, Rode R, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1KNA at the nadir. AIDS 1998; 12: F9-F14.
17. 17 Raboud J, Montaner JSG, Rae S, et al. Patients with higher baseline pVL are less likely to have virologic response in a meta-analysis of two trials of ZDV/ddI vs ZDV/ddI/NVP. 12th World AIDS conference, Geneva, June 28-July 3, 1998. 12361 (abstr).
18. 18 Staszerwski S, Morales-Ramirez J, Tashima K, et al. A phase III, multicentre, randomised, open label study to compare the antiretroviral activity and tolerability of Efavirenz (EFV)+Indianavir (IDV) versus EFV+Zidovudine (ZDV)+Lamivudine (3TC) versus IDV+ZDV+3TC at 24 weeks [Study DMP266-006]. 12th World AIDS conference, Geneva, June 28-July 3, 1998: 22336 (abstr).
19. 19 Deeks S, Loftus R, Cohen P, et al. Incidence and predictors of virologic failure to indinavir (IDV) and/or ritonavir (RTV) in an urban health clinic. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto: Canada, Sept 28-Oct 1, 1997: LB2 (abstr).
20. 20 Moyle G on behalf of the SPICE study team. Study of Protease Inhibitor combination in Europe (SPICE); saquinavir soft gelatin capsule (SVQ-SGC) and nelfinavir in HIV infected individuals. 12th World AIDS conference, Geneva, June 28-July 3, 1998: 12222 (abstr).
21. 21 DeMasi R, Staszewski S, Dawson D, Hill A. Control of HIV-1 RNA prevents clinical disease progression to AIDS. International workshop on HIV drug resistance, treatment strategies and eradication. St Petersburg: Florida, USA, 1997: 105 (abstr).
22. 22 Coakely E, Gilles J, Pendeault L, Dunkle L, Hammer S. Susceptibility of HIV-1 isolates derived from patients treated with didanosine (ddI) and stavudine (d4T). 4th Conference on Retrovirus and Opportunistic Infections. Washington DC, USA, Jan 22-26, 1997: 575 (abstr).
23. 23 Reijers MHE, Weverling GJ, Jurriaans S, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998; 352: 185-90.
24. 24 Moyle GJ. Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice. Expert Opin Investig Drugs 1997; 6: 943-64.
25. 25 Kaufmann D, Pantaleo G, Sucre P, Telenti A, for the Swiss HIV Cohort Study. CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998; 351: 723-24.
26. 26 Boucher CAB, Borleffs JC on behalf of the CHEESE study team. Long-term evaluation of saquinavir soft gel capsules or indinavir as part of a triple therapy regimen (cheese study). 12th World AIDS